COMTAN (entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 1999.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
COMTAN (entacapone) is an oral catechol-O-methyltransferase (COMT) inhibitor approved in 1999 for use as an adjunct to levodopa/carbidopa in Parkinson's disease patients experiencing motor fluctuations. It works by inhibiting the enzyme that breaks down dopamine, extending levodopa's therapeutic effect and reducing off-time symptoms.
As a mature adjunct therapy approaching loss of exclusivity, COMTAN faces declining commercial momentum with minimal linked job openings, indicating a consolidating or transitioning team structure.
Catechol O-Methyltransferase Inhibitors
Catechol-O-Methyltransferase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Pilot Study of Entacapone for Methamphetamine Abuse
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
Worked on COMTAN at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job openings and a lifecycle status of 'LOE Approaching,' COMTAN offers limited career momentum for growth-oriented professionals. Roles on this product are primarily defensive/maintenance-oriented, focused on protecting remaining market share and managing the transition to generics rather than driving innovation or expansion.